Funding
Funding not disclosed
Founders
Product
Problem
Traditional nanobody discovery is a time-intensive and costly process, often resulting in sequences encumbered by existing intellectual property. This limits the speed and cost-effectiveness of developing novel therapeutic and diagnostic agents.
Solution
Nanofoldr offers an AI-driven platform for generating high-affinity, patent-free nanobody sequences. The platform optimizes for binding affinity and desired biophysical properties, delivering novel candidates within days. This accelerates research and development pipelines by providing researchers with unique intellectual property for their projects.
Target Audience
The primary customers are researchers and developers in the biotechnology and pharmaceutical sectors requiring novel nanobodies for therapeutic and diagnostic applications.
Features
- Proprietary AI models trained to optimize for binding affinity and specific biophysical characteristics such as stability and solubility.
- Computational screening and validation algorithms to identify and rank top nanobody candidates.
- Generation of novel sequences ensuring freedom to operate and full intellectual property ownership for the user.
- Rapid turnaround time, delivering candidate sequences in days rather than months.
- In-silico analysis providing detailed structural and affinity data for experimental validation.